Finance

Lists
Z1TS34:BVMF
Zoetis Inc Bdr
R$30.49
0.00%
(0.00) 1D
Nov 16, 5:53:50 PM GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for Z1TS34...
Open
R$30.39
High
R$30.49
Low
R$30.18
Mkt. cap
34.29B
Avg. vol.
3.24K
Volume
10.22K
52-wk high
R$44.28
52-wk low
R$21.42
Shares outstanding
406.32M
No. of employees
14K
Open
R$30.39
High
R$30.49
Low
R$30.18
Mkt. cap
34.29B
Avg. vol.
3.24K
Volume
10.22K
52-wk high
R$44.28
52-wk low
R$21.42
Shares outstanding
406.32M
No. of employees
14K
News stories
From web sources and news partners
Profile
Zoetis Inc., headquartered in Parsippany, New Jersey, is the largest producer of medicine and vaccinations for pets and livestock worldwide. The company's products include antiparasitics, vaccines, products that relieve itch, anti-infectives, products that alleviate pain, animal health diagnostics, as well as hormones, cardiopulmonary, topical and oral hygiene therapeutics, central nervous system drugs, diuretics, antiemetic, euthanasia, and hepato-digestive products. The company has operations in over 50 countries. In 2025, 70% of the company's revenue came from products for pets and 29% of the company's revenues came from products for livestock. In 2025, 54% of the company's revenue came from customers in the United States. Of this revenue, 79% came from products for dogs and cats, 13% came from products for cattle, and 4% came from products for horses. In 2025, 46% of the company's revenue came from international customers. Of this revenue, 53% came from products for dogs and cats, 19% came from products for cattle, 9% came from products for swine, 7% came from products for poultry, and 3% came from products for horses. Wikipedia
About Zoetis Inc Bdr
CEOKristin C. Peck
Employees14.5K
Founded1952
HeadquartersParsippany-Troy Hills, New Jersey, United States
SectorHealth Care
IndustryPharmaceutical industry
Websitezoetis.com
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
2.39B
2.26B
2.47B
2.39B
Cost of goods sold
711.00M
640.00M
670.00M
696.00M
Cost of revenue
711.00M
640.00M
670.00M
696.00M
Research and development expenses
199.00M
180.00M
173.00M
174.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
618.00M
584.00M
589.00M
577.00M
Operating expense
848.00M
795.00M
793.00M
782.00M
Total operating expenses
1.56B
1.44B
1.46B
1.48B
Operating income
828.00M
827.00M
1.00B
913.00M
Other non operating income
-6.00M
-1.00M
-2.00M
-3.00M
EBT including unusual items
761.00M
758.00M
866.00M
729.00M
EBT excluding unusual items
780.00M
779.00M
948.00M
857.00M
Income tax expense
158.00M
157.00M
175.00M
138.00M
Effective tax rate
20.76%
20.71%
20.21%
18.93%
Other operating expenses
-
-
-
-
Net income
603.00M
601.00M
691.00M
591.00M
Net profit margin
25.26%
26.57%
28.00%
24.72%
Earnings per share
1.48
1.53
1.87
1.75
Interest and investment income
25.00M
21.00M
16.00M
17.00M
Interest expense
-57.00M
-62.00M
-61.00M
-62.00M
Net interest expenses
-32.00M
-41.00M
-45.00M
-45.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
903.00M
946.00M
1.12B
1.03B
Gain or loss from assets sale
-
-6.00M
-1.00M
-
Upcoming events
AI content may include mistakes. Learn more
Google apps